ArticleFrontiers in medicine2023
Dry eye disease severity and impact on quality of life in type II diabetes mellitus.
Article in Frontiers in medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 15 citations in OpenAlex.
- Effects of a Novel Dexamethasone Hydrogel Drug Delivery System on Cytokine and Mucin Expression in a Three-Dimensional In Vitro Conjunctival Inflammation Model.Investigative ophthalmology & visual science · 2026Article
- Toward automated assessment of conjunctival hyperemia: A semisupervised artificial intelligence approach.Annals of the New York Academy of Sciences · 2025Article
- Article
- Electronic device exposure and dry eye symptoms among medical and nonmedical Palestinian university students: a multicenter cross-sectional study of associated factors.BMC ophthalmology · 2025Article
- Association between dietary self-care adherence and depression among adults living with type 2 diabetes mellitus in Ghana: a cross-sectional study.Journal of health, population, and nutrition · 2025Article
- Evaluation of changes in objective visual quality based on tear film stability after SMILE surgery.Frontiers in medicine · 2025Article
- Fosfenopril Attenuates Inflammatory Response in Diabetic Dry Eye Models by Inhibiting the TLR4/NF-κB/NLRP3 Signaling Pathway.Investigative ophthalmology & visual science · 2024Article
- Recommendations for nutritional supplements for dry eye disease: current advances.Frontiers in pharmacology · 2024Review
- Dry Eye and Some Related Factors in Patients with Type 2 Diabetic Nephropathy: A Cross-Sectional Study in Vietnam.Clinical ophthalmology (Auckland, N.Z.) · 2024Article
- Individuals with Diabetes Mellitus Have a Dry Eye Phenotype Driven by Low Symptom Burden and Anatomic Abnormalities.Journal of clinical medicine · 2023Article
- Tear Fluid Biomarkers and Quality of Life in People with Type 2 Diabetes and Dry Eye Disease.Metabolites · 2023Article
Corrections and comments
- Erratum issued
Authors and funding
8 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: To assess the severity of dry eye disease (DED) in humans, its impact on quality of life (QoL) and to grade the damage incurred by the anterior ocular surface in patients diagnosed with type 2 diabetes mellitus (T2DM). Patients and methods: Forty-six patients (mean age ± SD = 63.8 ± 6.7 years) diagnosed with T2DM were enrolled in the experimental group and 26 healthy individuals constituted the control group (67.9 ± 8.9 years). The diagnosis and gradation of DED were conducted in accordance with the International Task Force severity grading scheme. Disease-specific questionnaires were used to obtain the Ocular Surface Disease Index (OSDI) and assess the negative effects of the disease on the patient's QoL. The severity of conjunctival redness and corneal/conjunctival staining was assessed by Efron and Oxford scales, respectively. Results: According to OSDI scores, the entire experimental group presented symptoms of DED: 54.4% were diagnosed with mild DED and 46.6% with moderately severe DED. No cases of severe DED were diagnosed in either the experimental or control group. In the control group, 57.7% of individuals did not have the disease. A significant difference between the experimental and control groups was recorded for both OSDI scores ( Conclusion: In comparison to healthy adults, DED adversely impacts the QoL of type 2 DM patients, regardless of the disease's association with keratopathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.